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Verteporfin photodynamic therapy combined 
with intravitreal triamcinolone for choroidal 
neovascularization due to angioid streaks
Purpose: To report the visual outcome of photodynamic therapy (PDT) combined with 
intravitreal triamcinolone acetonide (IVTA) for choroidal neovascularization (CNV) secondary 
to angioid streaks (AS).
Methods: Five eyes of five consecutive patients (mean age 45 ± 10 years) with CNV secondary 
to AS were treated by combination of PDT and IVTA. TA (4 mg/0.1 mL) was injected 7 days 
before PDT.
Results: All patients completed the 12-month follow-up. CNV was subfoveal in three cases and 
extrafoveal in two. Median best-corrected visual acuity (BCVA) was 0.3 LogMAR (70 letters) at 
baseline (range 1.3–0.1), and 0.5 LogMAR (60 letters) at the final examination (range 1.0–0.1). 
At 12 months, one patient had severe visual deterioration, with a loss of seven lines of VA; Two 
patients lost up to three lines. One patient had no change in BCVA and the fifth gained nine lines 
of VA. Two patients received one further combination of PDT and IVTA after the first combination 
treatment. All eyes showed the CNV closure at the 12-month follow-up visit.
Conclusions: Combination of PDT and IVTA may reduce the need for retreatment and could 
be potentially useful for preserving vision in some patients with CNV due to AS.
Keywords: ocular corticosteroids
Introduction
Angioid streaks (AS) represent breaks in Bruch’s membrane and are associated 
with various systemic diseases such as Ehlers–Danlos syndrome, Paget disease, and 
pseudoxanthoma elasticum (PXE).1 The main vision-threatening complication of AS 
is choroidal neovascularization (CNV) that develops in 72% to 86% of eyes.2,3 The 
natural history of CNV and its visual prognosis are poor with most eyes progressing 
to legal blindness. In addition, visual outcome after laser treatment or photodynamic 
therapy (PDT) with verteporfin is discouraging.1–5
PDT alone can occlude CNV , but tends to cause a transient inflammatory 
response and increase in capillary permeability along with an enhanced expression 
of vascular endothelial growth factor (VEGF) activity shortly after treatment that 
may limit its efficacy. The addition of intravitreal triamcinolone acetonide (IVTA), 
which, by reducing inflammation and inhibiting VEGF,6,7 seems to improve the 
visual outcomes in CNV secondary to age-related macular degeneration, may 
be useful even in the treatment of CNV secondary to AS. In this study we report the 
visual outcome of a series of patients with CNV secondary to AS treated by PDT 
combined with IVTA.
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Methods
We retrospectively analyzed five eyes of five consecutive 
patients (three men and two women; mean age 45 ± 10 years) 
with CNV due to AS, who underwent, at least 12 months 
before, 4 mg/0.1 mL IVTA injection followed, 1 week later, 
by standard PDT with verteporfin. Patients showing evidence 
of cutaneous PXE were included in this interventional study, 
if diagnosed with active CNV on fluorescein angiography 
(FA) examinations. Exclusion criteria included: 1) any other 
ocular diseases that could affect VA; 2) presence of age-related 
macular degeneration; 3) previous treatment, such as laser 
photocoagulation, PDT, IVTA injection, or any anti-VEGF 
treatment within the past 3 months; 4) evidence of external ocu-
lar infection including blepharitis, conjunctivitis, or chalazion; 
5) patients judged to be steroid responders. The patients signed 
a comprehensive consent form according to Good Clinical 
Practice guidelines, before proceeding with any examina-
tions and treatments. All subjects underwent a complete 
ophthalmologic examination including fundus biomicroscopy, 
fluorescein angiography (FA) and best-corrected visual acuity 
(BCVA) before and 1 week,1 month, then every 3 months after 
the combined therapy. BCVA was measured using standard 
Early Treatment of Diabetic Retinopathy Study (ETDRS) 
charts at 4 meters. Forced choice strategy was used to assess 
the BCVA threshold. The BCVA threshold was assigned when 
the patient was able to recognize four out of five characters per 
row.8 Optical coherence tomography (OCT 3000; Stratus, San 
Leandro, CA) was also performed at each visit. Retreatment 
decisions were made on the basis of: persistence or increase 
in leakage on FA frames, and/or persistence or increase in 
sub-retinal/intraretinal fluid on OCT scans, associated with a 
decrease of at least one ETDRS line of BCVA.
Results
Clinical details of patients and BCVA changes from baseline 
are summarized in Table 1. All CNV were actively leaking 
on FA, and were subfoveal in three cases, and juxtafoveal 
in the other two cases. Two eyes have been previously 
treated by PDT monotherapy at least 3 months before 
combination therapy. All patients completed the 12-month 
follow-up. Median BCVA was 0.3 LogMAR (70 letters) at 
baseline (range 1.3–0.1) and 0.5 LogMAR (60 letters) at 
the 12-month examination (range 1.0–0.1). Twelve months 
after the combination treatment, one patient showed severe 
visual deterioration, with a loss of seven ETDRS lines of 
visual acuity, and two patients lost up to lines. One patient 
had no change in BCVA and the fifth gained nine ETDRS 
lines. Two patients received one further combination of PDT 
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and IVTA injection after the first combination treatment 
(3 and 6 months, patient 1 and patient 2, respectively). All 
eyes showed the CNV closure at the 12-month follow-up 
visit, and no CNV enlargement as evaluated by FA and 
OCT (Figures 1–3). The two juxtafoveal CNV did not 
show subfoveal progression at the last follow-up. Mean 
OCT thickness was 320 micron at baseline and 250 micron 
at the 12-month follow-up visit. No side effects, such as 
uncontrolled intraocular pressure increase or cataract pro-
gression, were observed in any patient during follow-up. In 
all patients, fellow eyes did not develop active CNV during 
the study period.
Discussion
CNV is a serious complication of AS, with a poor visual 
prognosis. The current literature offers no clues as to the effect 
of PDT combined with IVTA for CNV secondary to AS. 
Here we present the results of our retrospective analysis 
of consecutive eyes treated by PDT combined with IVTA 
for CNV secondary to AS. Some studies suggest that laser 
photocoagulation may offer limited benefits for extrafoveal 
CNV, but probably does not change the long-term visual 
prognosis.4,5 For this reason we decided to include also 
the extrafoveal lesions, and not to treat them by laser 
photocoagulation.
In our series, at the 12-month follow-up visit, one 
patient experienced a severe visual loss, and two patients 
showed a moderate visual loss, due to scar development. 
One patient was stable (unchanged VA) and one patient 
showed an improvement in BCVA at 12 months. No 
correlation with previous PDT treatments, or CNV location, 
or BCVA at baseline was evident. Only two patients needed 
Figure 1 Left eye of patient 2. Black and white red-free photo A) shows peripapillary subretinal hemorrhages, and fluorescein angiography (FA) B) reveals the leakage 
from the neovascular complex (papillomacular region, and nasal to the optic disc), before receiving PDT/iVTA (best-corrected visual acuity 20/32 [0.2 LogMAr]). Twelve 
months after the 1st combined treatment (6 months after the 2nd combined treatment), best-corrected visual acuity was 20/63 (0.5 LogMAr), the red-free photo C) shows 
absorption of blood, and FA D) discloses a decrease in fluorescein leakage after regression of choroidal neovascularization.
Abbreviations: iVTA, intravitreal triamcinolone acetonide; PDT, photodynamic, therapy.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 2 Left eye of patient 4. Fluorescein angiography A) before receiving PDT/iVTA (best-corrected visual acuity 20/200 [1 LogMAr]). FA B) shows reduction of 
fluorescein leakage and decrease in size of choroidal neovascularization 1 year after PDT/IVTA. Best-corrected visual acuity was unchanged.
Abbreviations: iVTA, intravitreal triamcinolone acetonide; PDT, photodynamic, therapy.
Figure 3 right eye of patient 5. Color photo A) shows angioid streaks and subfoveal hemorrhages. Fluorescein angiography B) demonstrates the presence of choroidal 
neovascularization (CnV), and optical coherence tomography (OCT) C) reveals the neovascular complex as a high-reflective, red-yellow band in the subretinal space 
above the rPe/choriocapillaris layer, causing intra e subretinal exudation. Best-corrected visual acuity 20/400 [1.3 LogMAr]). Three months after PDT/iVTA: color photo   
D), fundus autofluorescence E), and OCT F) demonstrate restoration of foveal anatomy. Best-corrected visual acuity improved to 20/80 (0.6 LogMAr). One year after   
PDT/iVTA: color photo G), fundus autofluorescence H), and OCT I) show involution of CnV surrounded by some atrophic changes, and absence of blood and subretinal 
fluid. Best-corrected visual acuity was 20/50 (0.4 LogMAR).
Abbreviations: iVTA, intravitreal triamcinolone acetonide; rPe, retinal pigment epithelium; PDT, photodynamic, therapy.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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one more combined treatment over a 12-month follow-up 
period.
As reported in previous nonrandomized studies, IVTA 
reduces the frequency of PDT retreatment that could result 
from combining the short term effect of PDT-induced CNV 
closure with antiangiogenic and anti-inflammatory effects 
of intravitreal corticosteroids.6,7 Intravitreal triamcinolone 
acetonide is a corticosteroid with anti-inflammatory 
and antiangiogenic properties.9 IVTA monotherapy has 
shown a very limited beneficial effect for managing neo-
vascular AMD.10 However, IVTA in combination with PDT 
yielded favorable results by increasing VA, and lowering 
retreatment rate, in both pilot and randomized studies.11–13
In our series, IVTA was administered 7 days before 
PDT verteporfin therapy, to reduce intraretinal edema, thus 
increasing the photodynamic shutdown of CNV capillaries, 
and down-regulate PDT-mediated VEGF expression and 
inflammation. It is noteworthy that, in vitro studies have 
demonstrated that triamcinolone significantly reduced 
collagenase and proteoglycanase degrading activities, which 
was accompanied by inhibition of the expression of metal-
matrix-proteinases (MMP) 1 and 3.14,15 Furthermore, PXE 
fibroblasts have been shown, in vitro, to exhibit increased 
proteolytic and elastolytic functions16,17 as well as MMP-2 
activity18 that might lead to extracellular membrane degra-
dation, Bruch membrane fragmentation and finally promote 
aggressive CNV formation. Therefore, it may be that, in 
such patients, IVTA would counteract not only the PDT 
side effects (choroidal ischemia, inflammation and VEGF 
upregulation), but also the increased proteolytic activity 
involved in CNV pathogenesis in PXE.
Although our study is limited by the small number of 
patients and short follow-up, our results suggest that PDT 
with IVTA may reduce the need for retreatment and could 
be potentially useful for preserving vision. Combination 
therapy may be able to arrest the disease progression with 
a single session, as recently proposed by Ahmadieh et al19 
in AMD. However, side effects, even though not evident in 
this series, are well known and must always be taken into 
account.7
In the era of promising new intravitreal anti-VEGF 
treatments for patients suffering from neovascular age-
related macular degeneration, it is interesting to observe 
that in small uncontrolled case series published in the 
literature, such treatments seem to stabilize VA in eyes 
with CNV secondary to AS.20–24 At the beginning of the 
current study, anti-VEGF were not yet available, and given 
that visual outcome after PDT with verteporfin alone were 
discouraging,5 we decided to investigate the effects of PDT 
combined with IVTA. Today, we would probably favor 
anti-VEGF injections over combined IVTA and PDT in the 
treatment of such patients. However, long-term follow-up 
and randomized controlled studies are needed to assess 
the safety and efficacy of both combined IVTA and PDT, 
and multiple intravitreous injections of anti-VEGF drugs 
for the treatment of choroidal neovascular membranes 
secondary to AS.
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